Skip to content
OpenCapital
Get started

NewAmsterdam Pharma Company NAMS Deferred Revenue

Deferred Revenue at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$636.2M+2.7%

Other financials

Income statement

See full
Revenue$3.0M+2.1%
Operating income-$58.4M+15.2%
Net income-$48.4M-22.6%
EPS (diluted)-$0.40-17.6%

Balance sheet

See full
Cash & equivalents$457.6M-38.9%
Total debt$23.0K-94.1%
Total equity$665.2M-14.4%
Total assets$732.6M-10.5%

Cash flow

See full
Operating cash flow-$30.6M+16.1%
CapEx$38.0K+138%
Free cash flow-$30.6M+16.0%

Valuation

See full
Market cap$3.67B+63.7%

Profitability

See full
Operating margin-953.6%-3,536pp
Net margin-942.8%-3,477pp
FCF margin-630.1%-6,324pp

Returns & leverage

See full
Return on equity-29.5%-1.8pp
Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:DeferredRevenueCurrent.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NewAmsterdam Pharma Company's deferred revenue?
NewAmsterdam Pharma Company (NAMS) reported deferred revenue of $3.99M in Q1 2026.
How has NewAmsterdam Pharma Company's deferred revenue changed year-over-year?
NewAmsterdam Pharma Company's deferred revenue increased by 31.6% year-over-year, from $3.03M to $3.99M.
What is the long-term trend for NewAmsterdam Pharma Company's deferred revenue?
Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's deferred revenue has grown at a -5.9% compound annual growth rate (CAGR), from $4.79M to $3.99M.
What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.